Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04352205
Title Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Emory University
Indications

multiple myeloma

Therapies

Bortezomib + Daratumumab + Dexamethasone + Lenalidomide

Bortezomib + Daratumumab + Dexamethasone + Thalidomide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.